8-K: Quipt Home Medical Reports Fiscal Second Quarter 2025 Results: Adjusted EBITDA Strong at 23.3% of Revenue

Quipt Home Medical Corp. announces its fiscal second quarter 2025 financial results, with revenue decreasing but Adjusted EBITDA remaining strong at 23.3% of revenue.

Summary

• Quipt Home Medical Corp. reported its fiscal second quarter 2025 results, showing a revenue decrease of 6% to $57.4 million compared to $61.3 million in Q2 2024.
• The revenue decline was attributed to Medicare Advantage member withdrawals and a non-renewed disposable supply contract.
• However, the company saw improved momentum in volume exiting both March and April 2025.
• Recurring revenue remained strong at 81% of total revenue.
• Adjusted EBITDA decreased by 10% to $13.4 million (23.3% of revenue) compared to $14.9 million (24.3% of revenue) in Q2 2024.
• Net loss for Q2 2025 was ($3.0) million, or ($0.07) per diluted share, compared to ($0.7) million, or ($0.02) per diluted share, for Q2 2024.
• Cash flow from operations was $18.2 million for the six months ended March 31, 2025, compared to $14.9 million for the six months ended March 31, 2024.
• The company had $17.1 million of cash on hand as of March 31, 2025, and total credit availability of $30.7 million.
• The Net Debt to Adjusted EBITDA Leverage Ratio is 1.5x.
• The company served 146,000 unique patients as of March 31, 2025, a 2% year-over-year decrease.
• Quipt completed 203,000 unique set-ups/deliveries in Q2 2025, a 3% decrease from 210,000 in Q2 2024.
• Respiratory resupply set-ups/deliveries decreased 4% year-over-year, totaling 111,000 in Q2 2025.
• Two new De Novo sites were launched in Florida and Alabama.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue and EBITDA decreased, the company highlights strong recurring revenue, a healthy balance sheet, and strategic initiatives for future growth. Management's comments are optimistic about returning to a sustainable growth trajectory.

Positives

• Recurring revenue remains strong at 81% of total revenue.
• The company maintains a conservative balance sheet with a Net Debt to Adjusted EBITDA Leverage Ratio of 1.5x.
• Cash flow from operations increased to $18.2 million for the six months ended March 31, 2025, compared to $14.9 million for the same period in 2024.
• Quipt launched two new De Novo sites in Florida and Alabama, expanding its national footprint.
• The company successfully expanded its product portfolio with a new Medicare-approved airway clearance device.

Negatives

• Revenue decreased by 6% to $57.4 million in Q2 2025 compared to $61.3 million in Q2 2024.
• Adjusted EBITDA decreased by 10% to $13.4 million in Q2 2025 compared to $14.9 million in Q2 2024.
• Net loss for Q2 2025 was ($3.0) million, compared to ($0.7) million for Q2 2024.
• The customer base declined 2% year-over-year, serving 146,000 unique patients as of March 31, 2025, compared to 149,000 unique patients as of March 31, 2024.
• Unique set-ups/deliveries decreased 3% year-over-year.

Risks

• The company faces risks related to credit, market, liquidity, operational, reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy.
• General business and economic conditions in the regions in which the company operates could impact performance.
• The company's ability to execute on key priorities, including acquisitions and business retention, is a risk.
• Difficulty integrating newly acquired businesses could affect results.
• Disruptions in or attacks on the company's IT systems pose a risk.
• Changes in laws and regulations, including reimbursement rates, could negatively impact the company.
• Increased competition and changes in foreign currency rates are potential risks.
• The company's dependence on a few payors and key suppliers is a risk factor.
• Legal proceedings and litigation, including the civil investigative demand (CID) received from the Department of Justice, pose a risk.

Future Outlook

The company anticipates strong margin performance throughout the year and a return to historical organic growth levels in calendar 2025. They are focused on strengthening organic growth execution, expanding referral networks, and enhancing operational efficiency. Quipt aims to become the preferred provider for hospital discharge-driven care and is engaged in conversations with health systems.

Management Comments

• 'While our second quarter performance was softer than expected, we remain focused on returning to a sustainable growth trajectory,' said Gregory Crawford, Chairman and CEO of Quipt.
• Gregory Crawford stated that they have taken targeted actions to strengthen future organic growth execution, expand referral networks, and enhance operational efficiency.
• Hardik Mehta, CFO, stated that the company's financial strength gives them the flexibility to support organic growth initiatives and economically scale the business.
• Hardik Mehta expects the company's operational discipline to support strong margin performance throughout the year.

Industry Context

Quipt operates in the home medical equipment (HME) industry, providing respiratory care and other in-home monitoring and disease management services. The company's focus on respiratory care and chronic disease management aligns with the growing demand for these services due to an aging population and increasing prevalence of chronic conditions. The company's strategy of partnering with healthcare systems to become a preferred provider for hospital discharge-driven care reflects a trend towards integrated healthcare delivery.

Comparison to Industry Standards

• Comparing Quipt's Adjusted EBITDA margin of 23.3% to industry peers such as AdaptHealth (AHCO) and Rotech Healthcare can provide insights into its operational efficiency.
• AdaptHealth, for example, has reported adjusted EBITDA margins in a similar range, while Rotech's margins may vary depending on their specific business mix.
• The recurring revenue of 81% is a strong indicator of customer retention and stable revenue streams, which is a key metric for HME providers.
• Companies like Lincare Holdings also focus on recurring revenue through respiratory resupply programs.
• Quipt's Net Debt to Adjusted EBITDA Leverage Ratio of 1.5x indicates a conservative balance sheet compared to some peers that may have higher leverage ratios to fund acquisitions and growth.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and net loss, but reassured by the strong recurring revenue and management's plans for future growth.
• Employees may be affected by the company's efforts to enhance operational efficiency and improve sales team performance.
• Customers should benefit from the company's expanded product portfolio and focus on providing integrated care.
• Suppliers may be impacted by the company's efforts to optimize its cost structure.
• Creditors should be reassured by the company's conservative balance sheet and low leverage ratio.

Next Steps

• The company will host an earnings conference call on May 13, 2025.
• Quipt plans to focus on strengthening organic growth execution, expanding referral networks, and enhancing operational efficiency.
• The company aims to partner with healthcare systems to become the preferred provider for hospital discharge-driven care.
• Quipt will continue to pursue strategic initiatives, including health system partnerships.

Key Dates

Keywords

Quipt Home Medical, Financial Results, Adjusted EBITDA, Revenue, Home Medical Equipment, Respiratory Care, Recurring Revenue